Latest Strategic Outlook News

Berkeley Energia advances critical minerals exploration with promising lithium and rubidium findings at its Conchas Project, while escalating a $1 billion arbitration against Spain over uranium project permitting. Political shifts in Spain’s nuclear policy add a new dimension to the company’s strategic outlook.

Deterra Royalties reported a robust 44% jump in quarterly revenue to $89.1 million, driven by record iron ore royalties and advancing lithium project construction. The company’s diversified portfolio and strategic investments position it well for long-term growth.

PVW Resources reports exceptional near-surface rare earth grades and strong metallurgical recoveries at its Capão Bonito project in Brazil, advancing its rare earth portfolio and refining its strategic focus.

Tambourah Metals reports significant gold assay results extending mineralisation at Tambourah King and confirms high-grade antimony, silver, and copper at Speewah North, alongside corporate updates including a new CEO appointment and capital raising.

Mont Royal Resources reported a net cash outflow in Q2 2025 driven by one-off merger expenses, while outlining plans for a capital raising to support ongoing operations.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.

Astron Corporation Limited’s securityholders have overwhelmingly approved a scheme to shift the company’s domicile from Hong Kong to Australia, setting the stage for a significant corporate restructuring.

Aeris Environmental reported a robust 62% revenue increase in the June 2025 quarter, driven by new international contracts and expanding adoption of its Syncromesh IoT platform.

Orion Minerals reported significant cash outflows in its June 2025 quarter, with liquidity stretched and financing facilities nearly maxed out. The company is pursuing a $5.8 million capital raising to support ongoing operations following recent feasibility study completions.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

NGX Limited progresses its Malingunde graphite project with technical studies and stakeholder engagement, while uranium exploration permits advance in Namibia. The company stands to benefit from new US anti-dumping tariffs on Chinese graphite imports.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.